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The Nf2 tumor suppressor gene product merlin is re-
lated to the membrane-cytoskeleton linker proteins of
the band 4.1 superfamily, including ezrin, radixin, and
moesin (ERMs). Merlin is regulated by phosphorylation
in a Rac/cdc42-dependent fashion. We report that the
phosphorylation of merlin at serine 518 is induced by
the p21-activated kinase PAK2. This is demonstrated by
biochemical fractionation, use of active and dominant-
negative mutants of PAK2, and immunodepletion. By
using wild-type and mutated forms of merlin and phos-
pho-directed antibodies, we show that phosphorylation
of merlin at serine 518 leads to dramatic protein
relocalization.
Neurofibromatosis type 2 (NF2)1 is an inherited disorder
characterized by the development of Schwann cell tumors of
the eighth cranial nerve. Mutations and loss of heterozygosity
of the NF2 gene have been detected in NF2 patients and in
various sporadic tumors, including schwannomas, meningio-
mas, and ependymomas (1). In further support of a role for NF2
in tumor suppression, mice heterozygous for an Nf2 mutation
are predisposed to a wide variety of tumors with high meta-
static potential (2). In a separate model in which Nf2 is inac-
tivated specifically in Schwann cells, mice develop schwanno-
mas and Schwann cell hyperplasia (3).
The longest and predominant splice form of the Nf2 gene
codes for a 595-amino acid protein highly similar to the band
4.1 family of proteins. It is most closely related to the ERM
proteins, moesin, ezrin, and radixin. The ERM proteins are
thought to function as cell membrane-cytoskeleton linkers and
are localized to cortical actin structures near the plasma mem-
brane such as microvilli, membrane ruffles, and lamellipodia
(4, 5). Likewise, merlin is localized to cortical actin structures,
in patterns that partially overlap with the ERMs (1). It has
been proposed that intramolecular binding of the N-terminal
and C-terminal domains conformationally regulates the ERM
proteins by masking binding sites for interacting proteins. The
ERMs can also form homodimers and heterodimers, among
themselves and with merlin, adding an additional level of com-
plexity to the regulation of these proteins (6). The recently
solved crystal structure of the moesin N/C-terminal complex
strengthens this model of conformational regulation (7). Given
the sequence and, most likely, structural similarities of merlin
to the ERM proteins, it is possible that merlin itself could be
regulated in a similar fashion.
Recent studies (8, 9) have implicated additional factors in the
regulation of the ERMs, including phospholipids and phospho-
rylation. Previous work from our group and others (10, 11) has
shown that merlin is differentially phosphorylated as well and
that merlin protein levels are affected by growth conditions
such as cell confluency, loss of adhesion, or serum deprivation.
Merlin is found in an hypophosphorylated form when the com-
bination of cellular and environmental conditions are growth-
inhibitory (10). ERMs can be phosphorylated by Rho kinase,
and this phosphorylation can affect intramolecular association
and cellular localization. Phosphorylation and/or phospholipids
may promote the transition of the proteins to an active form by
“opening” intra- and intermolecular associations. These active
monomers can then bind to other interacting proteins and the
actin cytoskeleton and induce actin-rich membrane projections
(5, 8, 12, 13). The induction of merlin phosphorylation by acti-
vated alleles of the Rho family GTPases has also been exam-
ined. Interestingly, although activated Rho did not induce no-
ticeable phosphorylation of merlin, activated forms of Rac and
cdc42 did. The site of Rac-induced phosphorylation was deter-
mined to be a serine at position 518; mutation of serine 518
results in reduced basal phosphorylation and eliminated Rac-
induced phosphorylation (11).
Although Rac and cdc42 are implicated in the regulation of
many pathways, they are most associated with regulation of
cytoskeleton reorganization and gene expression (for recent
reviews see Refs. 14–16). In light of the data demonstrating
that activated Rac/cdc42 leads to phosphorylation and possible
inactivation of merlin, the elucidation of the responsible effec-
tor pathways and their effects on merlin function are of major
importance. Understanding this regulation of merlin could lead
to a more complete appreciation of the effects of merlin loss in
tumors.
MATERIALS AND METHODS
Plasmids and Transfections—Wild-type merlin and S518A were sub-
cloned from previously described vectors (10) into the BamHI-EcoRI
sites of pCDNA3 (Invitrogen). The GST-merlin recombinant substrates
were prepared by PCR amplification of the 60 amino acid coding se-
quences from the wild-type and S518A versions of merlin (primer se-
quences are available upon request) and subcloned into EcoRI and XhoI
sites of pGEX5-3x. Wild-type PAK2 was amplified and cloned into the
BamHI and XhoI sites of pCDNA3 (Invitrogen). Activated PAK2 was
made by inserting the T402E mutation by site-directed mutagenesis
using the Quick-change kit, as instructed by the manufacturer (Strat-
agene). The PAK2 auto-inhibitory domain (amino acids 82–146) was
amplified and cloned into pCDNA3. All plasmids were verified by DNA
sequencing. Transfections were done with LipofectAMINE (Invitrogen).
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Antibodies—The antibodies used are as follows: commercial merlin
antibody SC331 (Santa Cruz Biotechnology); PAK1-SC882, PAK2-
SC1872, and PAK3-SC1871 (Santa Cruz Biotechnology). SC1871 was
demonstrated to be specific by Western blot comparison of extracts from
cells overexpressing PAK1–3 (not shown). SC882 has been shown to be
specific for PAK1 using PAK1/ mouse embryo fibroblasts.2 SC1872
may also react with PAK1; however, this does not affect the conclusion
drawn from the immunodepletion experiments shown in Fig. 3.
In Vitro Kinase Assay and Immunodepletion—Total cellular extracts
were prepared by lysing the cells in cell lysis buffer: 50 mM HEPES, pH
7.4, 1% Nonidet P-40, 150 mM NaCl, 25 mM NaF, 20 mM -glycerophos-
phate, 1 mM EDTA, and protease inhibitors. The extracts were added
into reactions containing 200 ng of GST substrate, 2 mM MgCl, 2 mM
DTT, 100 M cold ATP, and 10 Ci of [-32P]ATP. For the immunodeple-
tion experiments extracts were incubated with the relevant antibody for
3 h at 4 °C. After four sequential exchanges of antibody, the presence of
the protein in question was determined by Western blot analysis of both
supernatant and the precipitate. Kinase reactions were carried out at
30 °C for 20 min. The substrate was washed 3 times in lysis buffer at
4 °C, and the reaction was terminated with protein sample buffer and
boiling for 5 min. The samples were then resolved by SDS-PAGE and
exposed to film.
Merlin Phosphorylation—In the in vivo studies, cells were trans-
fected with various expression vectors and harvested after 48 h into
SDS boiling buffer (10 mM Tris, pH 7.5, 50 mM NaF, 1% SDS). Cells
were scraped off the plates and boiled for 5 min; protein concentration
was determined by the BCA method (Pierce); and proteins were re-
solved by 9% SDS-PAGE and detected by Western blot analysis. Phos-
phatase treatment was described previously (10).
Production of Merlin Phospho-specific Antibodies—A chemically
phosphorylated peptide (H-CKDTDMKRLS*MEIE-NH2; *  serine is
phosphorylated) was coupled to SulfoLink coupling gel (Pierce) and
used to immunize rabbits. A standard protocol of immunization was
employed. Sera were purified by first passing it over an affinity column
of the phospho-antigen (binding antibodies recognizing the peptide,
phosphorylated and unphosphorylated). In a second step, the bound
fraction was applied to a second column of the unphosphorylated pep-
tide. The flow-through was collected and found to contain only phospho-
specific antibodies.
Biochemical Fractionation of Merlin Kinase Activity—For ion-ex-
change chromatography, a Q-Sepharose (Amersham Biosciences) 10 
10 column was run at pH 8.5 (diethanolamine buffer) and a linear NaCl
gradient, with maximal activity eluting around 120–130 mM. A 60-fold
enrichment was achieved with overall recovery of about 70%. For dye-
ligand chromatography a Matrex Red A dye (Millipore) 10  10 column
was used (pH 8, 0–500 mM KCl linear gradient), which gave 10-fold
enrichment with 25% recovery.
Immunofluorescence—NIH3T3 or LLC-PK1 cells were plated on
glass coverslips and transfected with various expression vectors. 24-h
post-transfection cells were fixed in 4% paraformaldehyde for 15 min
and permeabilized with Triton X-100 for 10 min. Sc331 was used at
1:1000 dilution, and HM2175 was used at 1.0 g/ml.
RESULTS
In Vivo Phosphorylation of Merlin by PAKs—Merlin phos-
phorylation is regulated in response to various stimuli (10), and
phosphorylation of serine 518 can be induced in a Rac/cdc42-
dependent manner (11). To identify the kinase that phospho-
rylates merlin on serine 518, NIH3T3 cells were co-transfected
with expression vectors for merlin and the constitutively active
forms of Rac/cdc42 kinase effectors. These included PAK1,
PAK2, PAK3, MLK3, LIM kinase, MEKK1, and JNK. Extracts
were made 48 h post-transfection and analyzed by Western blot
analysis. As shown in Fig. 1A, PAK1–3 induced an increase in
the slower migrating and hyperphosphorylated form of merlin
(see also Ref. 11). All other effectors tested did not induce
merlin phosphorylation and were confirmed as active with an
independent substrate (not shown). This phosphorylation is
serine 518-specific as the merlin S518A mutant, in which ser-
ine 518 was changed to alanine, runs as a single band corre-
sponding to the hypophosphorylated from of wild-type merlin
in the presence of the activated PAK kinases (Fig. 1A).
PAK2 Levels Correlate with Merlin Kinase Activity—To dis-
criminate between the different PAKs as candidate merlin
kinases in NIH3T3 cells, we set out to purify the kinase activity
over a series of chromatographic steps employing extracts from
untransfected NIH3T3 cells that were serum-stimulated. To-
ward this goal, an in vitro kinase assay was established. The
assay employs a recombinant substrate composed of residues
478–535 of merlin fused to glutathione S-transferase (GST).
The recombinant substrate was purified from bacteria and
then used in an in vitro kinase assay bound to glutathione-
agarose beads. Activity is determined by SDS-PAGE and auto-
radiography. This assay is highly specific for the merlin kinase,
as the S518A version of the substrate was not phosphorylated
to a significant extent under conditions that have been shown
to induce merlin phosphorylation (Fig. 1B). After an initial step
of ammonium sulfate precipitation, the precipitate containing
the activity was separated by ion-exchange chromatography on2 J. Chernoff (Fox Chase Cancer Center), personal communication.
FIG. 1. In vivo analysis of merlin phosphorylation by PAKs. A,
merlin Western blot analysis of extracts from NIH3T3 cells transfected
with expression vectors for wild-type (w.t.) or S518A merlin along with
activated (*) PAK1–3. Arrows indicate the different phosphorylated
(phospho.) forms of merlin. B, in vitro kinase assay with extracts from
NIH3T3 cells that were serum-stimulated (Ind.) or not stimulated
(N.I.). The merlin kinase activity was determined using the wild-type
(W.T.) GST-merlin recombinant substrate or the S518A mutant version
of this substrate. C, merlin Western blot analysis of extracts prepared
from NIH3T3 cells transfected with active Rac mutant (RacL61) or
active cdc42 (cdc42V12) and full-length merlin, alone or in combination
with the PAK2 autoinhibitory domain (AID). D, NIH3T3 extracts were
immunodepleted with PAK1, PAK2, or PAK3 antibodies and analyzed
by Western blot with a PAK2 antibody. The merlin kinase activity in
the treated extracts was determined by an in vitro kinase assay with
the merlin GST-pseudo-substrate and resolved by SDS-PAGE (See “Ma-
terials and Methods” for details of immunodepletion). IP, immuno-
precipitation.






















a Q-Sepharose column. Fractions were then examined for mer-
lin kinase activity using the in vitro kinase assay and for PAK1,
PAK2, and PAK3 levels by Western blotting. As shown in Fig.
2A, the maximal activity of merlin kinase was found in frac-
tions 20–22 in this separation. PAK2 levels also peaked in
fractions 20–22, whereas PAK1 levels peaked in fractions 23–
27, and PAK3 levels peaked around fraction 30. Fractions
20–22 were taken from the ion exchange and used in a subse-
quent step of dye-ligand chromatography. Maximal activity of
merlin kinase was observed in fractions 18–22. Again, PAK2
was present in a pattern that fully overlaps with the peak of
merlin kinase activity (Fig. 2B), whereas PAK1 and PAK3 were
no longer evident in these fractions (not shown). After four total
steps of enrichment, which included ammonium sulfate precip-
itation, ion-exchange, dye-ligand chromatography, and gel fil-
tration, more than 1200-fold enrichment of the kinase activity
was achieved. When assessing the fractions of the various
chromatographic steps by Western blot analysis, PAK2 levels
consistently paralleled merlin kinase activity (Fig. 2 and not
shown). Thus, by chromatographic separation, we were able to
separate PAK1–3 and demonstrate that the merlin kinase ac-
tivity from NIH3T3 cells co-fractionates with PAK2.
The PAK Auto-inhibitory Domain Inhibits the Rac-dependent
Phosphorylation of Merlin—The N-terminal regulatory domain
of the PAKs has been shown to contain an auto-inhibitory
domain (AID), which can act in trans (17). The inhibitory frag-
ment in PAK2 resides between residues 82 and 146 (equivalent
to the 83–149 AID of PAK1). To investigate further the role of
PAK2 in induction of merlin phosphorylation in response to
Rac/cdc42, we assessed the ability of the AID to inhibit this
activity. NIH3T3 cells were co-transfected with expression vec-
tors for full-length merlin, activated Rac or cdc42, and the
PAK2 AID. The inclusion of the PAK2 AID significantly re-
duced the phosphorylation of merlin, as evident by the 3–4-fold
decrease in the ratio of hyperphosphorylated to hypophospho-
rylated merlin in cells expressing the AID (Fig. 1C). These data
indicate that merlin kinase activity induced by Rac/cdc42 is
sensitive to PAK inhibition and strengthen the claim that
PAK2 is the responsible kinase downstream of Rac in NIH3T3
cells.
Reduced Merlin Kinase Activity following Immunodepletion
of PAK2—As another approach to address whether PAK2 is
directly responsible for merlin phosphorylation in this cell sys-
tem, the enzyme was immunodepleted from extracts of serum-
treated NIH3T3 cells. After four sequential rounds of immuno-
precipitation, the amount of PAK2 in the extract was reduced,
on average, by 2–3-fold (Fig. 1D). Treated extracts were then
used in kinase assays with the GST-merlin recombinant sub-
strate; activity was determined by SDS-PAGE and autoradiog-
raphy. As shown in Fig. 1D, extracts immunodepleted for PAK2
(IP-PAK2) show a 2–3-fold reduction in kinase activity com-
pared with those treated in a similar fashion without antibody
FIG. 2. Chromatographic separa-
tion of merlin kinase activity. Merlin
kinase activity was separated on a
Q-Sepharose 10  10 column. A, fractions
were monitored for activity by in vitro
kinase assay using the GST-merlin re-
combinant substrate and by Western blot
analysis for PAK1, PAK2, and PAK3. B,
in a subsequent step, fractions 20–24
were further resolved on a Matrex Red
dye-ligand column. Kinase activity and
PAK2 levels were followed. L, load
fraction.






















added. Also, the immunodepletion of PAK3 (IP-PAK3) or PAK1
(IP-PAK1) from these extracts had little or no effect on merlin
kinase levels of activity (Fig. 1D). This demonstrates the re-
quirement for PAK2 for the phosphorylation of merlin serine
518 under these conditions.
Generation of Merlin Phospho-specific Antibodies—To follow
the function and localization of merlin phosphorylated at serine
518, we produced antibodies (HM2175) that preferentially rec-
ognize the phosphorylated form (see “Materials and Methods”).
To assess the activity of this antiserum, protein extracts from
LLC-PK1 cells ectopically expressing wild-type merlin were
used in Western blot analysis with either SC331 or HM2175
antibodies. The SC331 antibody detected both the hypo- and
hyperphosphorylated form of merlin, whereas the HM2175 an-
tibody preferentially detected the hyperphosphorylated form of
the protein (Fig. 3A). At high concentrations of merlin,
HM2175 did recognize the hypophosphorylated form to some
extent (Fig. 3A). To validate further the specificity of HM2175,
merlin was ectopically expressed along with active PAK2 in
NIH3T3 cells, immunoprecipitated, and analyzed by Western
blot, before and after treatment with phosphatase. As shown in
Fig. 3B, reactivity of the HM2175 antibody was significantly
reduced following phosphatase treatment, whereas the non-
phospho-directed SC331 antibody recognized merlin forms in
all lanes.
The phospho-directed antibodies were tested for specificity
in immunocytochemistry. LLC-PK1 cells were transfected
with vectors expressing either wild-type merlin or the merlin
S518A mutant. Fixed cells were then incubated with either
the SC331 or HM2175 antibodies. Although SC331 recog-
nized both merlin forms (Fig. 3C, panels 1 and 2), the
HM2175 antibody recognized only ectopic wild-type merlin
(Fig. 3C, panels 5 and 6). This pattern was observed in many
cell lines of both epithelial and fibroblastic origin (not
shown). Thus, the HM2175 antibodies preferentially recog-
nize the phosphorylated form of merlin both in Western blot
analysis and immunocytochemistry.
Phosphorylation Leads to Changes in the Subcellular Local-
ization of Merlin in LLC-PK1 Cells—To visualize subcellular
localization of the different forms of merlin, LLC-PK1 epithe-
lial cells were transfected with wild-type merlin or the merlin
S518A or S518D (phospho-mimicking) mutants and incubated
with the SC331 antibody. As shown in Fig. 3C (panel 1), wild-
type merlin mainly localized to microvilli. Lower amounts of
the protein were present in larger membrane protrusions and
in cortical actin structures. Similar results were obtained with
the S518A mutant (panel 2). However, the S518D mutant was
localized predominantly in the larger membrane protrusions
(panel 3). Likewise, a shift to the larger membrane protrusions
was observed when wild-type merlin was co-transfected with
active PAK2 to increase merlin phosphorylation (panel 4). Im-
portantly, the localization of the S518A mutant was not af-
fected by co-transfected PAK2 (not shown), indicating that
phosphorylation of serine 518 is required for relocalization. To
FIG. 3. Phosphoserine 518 antibod-
ies and subcellular localization of
merlin. Western blot analysis of exoge-
nous wild-type merlin expressed in LLC-
PK1 cells. A, Western blot analysis of in-
creasing amounts of protein extract from
transfected LLC-PK1 cell showing the
specificity of the HM2175 antibody to-
ward the slower migrating, phosphoryl-
ated form of merlin. B, Western blot anal-
ysis of merlin immunoprecipitated from
NIH3T3 cells transfected with a vector for
wild-type merlin alone (W.T.) or with a
vector for active PAK2 (PAK2). Half of the
protein from the merlin plus active-PAK2
immunoprecipitate was treated with
phosphatase (PAK2  PP). C, immunolo-
calization of merlin with SC331 and wild-
type merlin (panel 1), merlin S518A (pan-
el 2), merlin S518D (panel 3), wild-type
merlin plus active PAK2 (panel 4) and
staining with HM2175 of wild-type mer-
lin (panel 5) and merlin S518A (panel 6).
SC331, commercial antibodies (Santa
Cruz Biotechnology); HM2175, phospho-
directed antibodies. Arrows indicate the
membrane protrusions to which merlin
relocalized.






















confirm this observation, HM2175 was used to stain cells trans-
fected only with wild-type merlin. As expected, the HM2175
antibody stained wild-type merlin mainly in the larger cellular
protrusions (panel 5). This reinforces the observation that the
phosphorylation of serine 518 is required for the redistribution
of merlin and is not a consequence of simply mutating serine
518 to aspartic acid.
DISCUSSION
We present here several independent lines of evidence sup-
porting PAK2 as the kinase responsible for phosphorylation of
serine 518 on the Nf2 tumor suppressor gene product, merlin.
Of all Rac/cdc42 kinase effectors tested only PAK1–3 induced
the phosphorylation of merlin serine 518 in vivo. We were able
to separate PAK2 from PAK1 and PAK3 biochemically and
demonstrate that merlin kinase activity co-elutes in parallel
with PAK2 in NIH3T3 cells. The use of the dominant-negative
fragment (PAK2-AID) and immunodepletion of PAK2 directly
reinforce the identification of PAK2 as the merlin kinase. Ad-
ditional circumstantial evidence can be found in the amino acid
context of the serine 518 in merlin (MKRLSM) and is similar to
many PAK recognition sites such as the pHOX p47 site
(RKRLSQ), which has been shown to be an in vivo substrate of
the PAKs (18).
By using the generic anti-merlin antibody SC331, wild-type
protein and the S518A mutant were observed mostly localized
to microvilli and to a small number of larger membrane pro-
trusions and cortical structures in LLC-PK1 cells. However,
when the merlin S518D mutant or wild-type merlin plus active
PAK2 were introduced into these cells, a marked redistribution
of merlin to membrane protrusions was observed. The HM2175
antibodies stained wild-type merlin in a similar pattern as the
SC331-based staining of the merlin S518D mutant or wild-type
merlin in the presence of active PAK2. The localization of
phosphorylated merlin to such protrusions is not exclusive as
phospho-merlin can still be observed in microvilli and cortical
actin at a somewhat reduced level. The redistribution was
dependent on phosphorylation of serine 518, because the mer-
lin S518A mutant transfected with active PAK2 did not shift
localization. This redistribution of merlin is highly reminiscent
of the redistribution of ezrin in response to phosphorylation
(12).
The data presented here are consistent and complementary
to recent data demonstrating induction of serine 518 phospho-
rylation by Rac/cdc42 (11). The identification of PAK2, which
can be directly activated by Rac/cdc42, as the merlin kinase
functionally connects merlin with the Rac/cdc42 pathway. That
merlin can inhibit Rac-induced signaling and that the imme-
diate downstream effector, PAK2, phosphorylates and, per-
haps, inactivates merlin reinforces the possibility of a “feed-
forward” mechanism. In such a model, merlin would function at
steady-state to down-regulate Rac/cdc42-induced signaling.
Once activated, Rac/cdc42 would activate PAK2, which in turn
would phosphorylate merlin and relieve its inhibitory effect on
Rac/cdc42. Functionally, this could be achieved by different
mechanisms and impinge on these pathways at different levels
(11). Merlin could inhibit signaling by acting upstream or upon
effectors downstream to Rac/cdc42, or both. This would not be
unprecedented as it has been suggested that activation of
ERMs is required for the activation of Rho by lysophosphatidic
acid and that Rho, in turn, induces phosphorylation of the
ERMs (19). The observed shift in merlin localization after phos-
phorylation of serine 518 raises the possibility that merlin
controls the subcellular localization of a molecule such as
RhoGDI is worthy of consideration.
It is reasonable to suggest that the inhibitory function of
merlin on Rac/cdc42-signaling is critical to its tumor suppres-
sor function, as Rac signaling is closely linked to cellular trans-
formation (20). For example, Rac activation is required for the
full transformed phenotype induced by Tiam and Ras (21–24).
Rac and its regulators have also been shown to regulate cell
motility and invasiveness (25). Examples include increased
metastatic potential of cells expressing activated Rac (26) and
identification of the Rac-GEF, Tiam, as a promoter of invasive-
ness (21, 27, 28). The fact that Nf2/ mice have highly met-
astatic tumors (2) with loss of the wild-type Nf2 allele is also
consistent with loss of merlin leading to activation of the Rac
signaling pathways.
Although implicated in various cellular processes, the roles
of the different members of the PAK family are not well de-
fined. The identification of substrates specific to the different
PAKs is one method of defining their specific functions. Pres-
ently, Raf-1 is a known PAK2 substrate and Bad and LIM
kinase are specific substrates of PAK1 (29–31). This differen-
tial activity may reflect different cell types and/or environmen-
tal conditions used in specific experiments or may reflect true
functional differences between the effector kinases. The iden-
tification of PAK2 as the kinase involved in merlin regulation
and localization is a strong link between the well established
Rac/cdc42 signaling pathways with a tumor suppressor gene of
unknown function. The further elucidation of these mecha-
nisms will, undoubtedly, lead to a better understanding of
merlin function and may suggest therapeutic strategies for
Nf2-deficient tumors.
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